Among all the parameters included in the analysis (Δ133p53β, TP53 mutation, tumor grade, lymph node metastasis and tumor size [>20 mm]), Δ133p53β stood out as the most significant independent predictor of cancer recurrence and death within the luminal-A subgroup regardless of TP53 mutation status or presence of lymph node metastasis (Hazard ratio [HR], 7.93; 95% CI, 2.52 to 25; p<4.31 10–4; [HR], 3.29; 95% CI, 1.125 to 9.63; p<0.03, Table 5B, respectively). This evidence concerns the gene TP53 and metastatic malignant neoplasm in the lymph nodes.